Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

I2286

Sigma-Aldrich

Irbesartan

≥98% (HPLC), powder

Sinonimo/i:

2-Butyl-3-[[2′-(2H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one, Avapro, BMS-186295, SR-47436

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali

Scegli un formato

10 MG
89,60 €
50 MG
351,00 €

89,60 €


A magazzinoDettagli


Richiedi un ordine bulk

Scegli un formato

Cambia visualizzazione
10 MG
89,60 €
50 MG
351,00 €

About This Item

Formula empirica (notazione di Hill):
C25H28N6O
Numero CAS:
Peso molecolare:
428.53
Numero MDL:
Codice UNSPSC:
12352200
ID PubChem:
NACRES:
NA.77

89,60 €


A magazzinoDettagli


Richiedi un ordine bulk

Livello qualitativo

Saggio

≥98% (HPLC)

Stato

powder

Colore

white to off-white

Solubilità

DMSO: >25 mg/mL

Ideatore

Bristol-Myers Squibb
Sanofi Aventis

Temperatura di conservazione

2-8°C

Stringa SMILE

CCCCC1=NC2(CCCC2)C(=O)N1Cc3ccc(cc3)-c4ccccc4-c5nnn[nH]5

InChI

1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)
YOSHYTLCDANDAN-UHFFFAOYSA-N

Informazioni sul gene

human ... AGTR1(185)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Descrizione generale

Irbesartan comprises bipentyl-tetrazole side chain. It is an imidazole derivative with high bioavailability and is metabolized by the enzyme cytochrome P450 2C9 isoenzyme in liver to be majorly eliminated by oxidation and glucuronidation.[1]

Applicazioni

Irbesartan has been used as an angiotensin II receptor type 1 (ATR1) blocker in carotid atheroma tissue.[2][3][4] It may be used to test its effect on allergic asthma in rat and mice mast cells.[5]

Azioni biochim/fisiol

Irbesartan is an angiotensin II type 1 (AT1) receptor antagonist with antihypertensive activity.[1] It also elicits selective peroxisome proliferator-activated receptor γ (PPARγ)-modulating activity and possesses anti-inflammatory properties.[1] Irbesartan shows protective cardiovascular effects[1] and provides protection against chronic glomerulonephritis.[5]

Caratteristiche e vantaggi

This compound is featured on the Angiotensin Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Bristol-Myers Squibb and Sanofi Aventis. To browse the list of other pharma-developed compounds, Approved Drugs, and Drug Candidates, click here.

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable


Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 9

1 of 9

Olmesartan ≥98% (HPLC)

Sigma-Aldrich

SML1394

Olmesartan

Irbesartan impurity A European Pharmacopoeia (EP) Reference Standard

Y0001156

Irbesartan impurity A

Azilsartan ≥98% (HPLC)

Sigma-Aldrich

SML0432

Azilsartan

Valsartan British Pharmacopoeia (BP) Reference Standard

BP1161

Valsartan

Ambrisentan ≥98% (HPLC)

Sigma-Aldrich

SML2104

Ambrisentan

Valsartan Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1315

Valsartan

Losartan Potassium Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1602

Losartan Potassium

Marie Hudson et al.
Pharmacotherapy, 27(4), 526-534 (2007-03-27)
To examine the class effect of angiotensin II receptor blockers (ARBs) on mortality in patients with heart failure who were aged 65 years or older. Retrospective population-based study. Administrative database that stores information on hospital discharge summaries for the Canadian
Jian-Ming Chen et al.
International journal of molecular sciences, 21(3) (2020-02-12)
In this study, we explored the release characteristics of analgesics, namely levobupivacaine, lidocaine, and acemetacin, from electrosprayed poly(D,L-lactide-co-glycolide) (PLGA) microparticles. The drug-loaded particles were prepared using electrospraying techniques and evaluated for their morphology, drug release kinetics, and pain relief activity.
Paula Clancy et al.
Journal of atherosclerosis and thrombosis, 23(7), 773-791 (2016-03-08)
Matrix metalloproteinases (MMPs), angiotensin II (AII) and its receptors are implicated in atherosclerotic plaque instability, however the roles of the two receptor subtypes, ATR1 and ATR2, in MMP regulation remain uncertain. In this study, we investigated the effect of ATR1
Guru Prasad Sharma et al.
International journal of radiation oncology, biology, physics, 113(1), 177-191 (2022-01-31)
Radiation-induced lung injury is a major dose-limiting toxicity for thoracic radiation therapy patients. In experimental models, treatment with angiotensin converting enzyme (ACE) inhibitors mitigates radiation pneumonitis; however, the mechanism of action is not well understood. Here, we evaluate the direct
Zhongqi Dong et al.
Molecular pharmaceutics, 10(3), 1008-1019 (2013-01-24)
The hepatic bile acid uptake transporter sodium taurocholate cotransporting polypeptide (NTCP) is less well characterized than its ileal paralog, the apical sodium dependent bile acid transporter (ASBT), in terms of drug inhibition requirements. The objectives of this study were (a)

Domande

Recensioni

Nessuna valutazione

Filtri attivi

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.